Medibase
EN VI JA

Medicines

Tendering & Market Access

Public procurement of medicines under the 2023 Bidding Law and Circular 40/2025/TT-BYT, and reimbursement through Vietnam Social Security (BHYT).

Overview

This section is a Vietnam-focused reference for public procurement and market access of medicines, governed by the Ministry of Health (Bộ Y tế) and Vietnam Social Security (Bảo hiểm Xã hội Việt Nam — BHYT).

Scope:

  • Tender group classification — 5 groups for chemical and biological generics, 4 groups for herbal and traditional medicines — based on GMP standard (EU-GMP, PIC/S-GMP, WHO-GMP), origin, bioequivalence data, and reference-biologic status.
  • Centralized procurement at national level (Trung tâm Mua sắm tập trung thuốc Quốc gia — NCDPC, under MOH), provincial centralised procurement, and individual healthcare-facility tenders.
  • Inclusion in the BHYT-reimbursable drug list (Circular 20/2022/TT-BYT) and payment ratios/conditions by hospital tier.
  • Hospital classification (Tier I/II/III/IV and special hospitals) and which tender groups each tier may procure from.
  • Original brand-name drugs (biệt dược gốc) and reference biologicals — conditions under which public facilities may procure them.
  • Price negotiation route for selected high-cost medicines.

The post-2023 framework — Bidding Law 22/2023/QH15, Decree 24/2024/NĐ-CP, and Circular 40/2025/TT-BYT — replaced the previous regime (Circulars 15/2019 → 07/2024 → 40/2025) to address chronic drug-supply disruptions caused by tender delays and to formalise mid-contract drug substitution.

Key documents

Procurement law:

  • Law on Bidding No. 22/2023/QH15 — issued 23 June 2023, effective 1 January 2024. Replaces the 2013 Bidding Law (43/2013/QH13). Article 55 carries provisions specific to drug, chemical, testing-reagent, and medical-equipment procurement.

Implementing decree:

  • Decree 24/2024/NĐ-CP — issued 27 February 2024. Detailed implementation of the Bidding Law on contractor selection, with a dedicated chapter on pharmaceutical procurement.

Drug tendering — current authority:

  • Circular 40/2025/TT-BYT — effective 25 October 2025. Replaces Circular 07/2024/TT-BYT in full. Drug bidding at public medical facilities; aligned with Pharmacy Law 44/2024/QH15. Five tender groups for chemical/biological generics, four for herbal and traditional medicines. Introduces mid-contract drug-substitution rules and updated provisions for traditional medicines and medicinal materials.

Drug tendering — historical (superseded):

  • Circular 07/2024/TT-BYT — issued 17 May 2024; in force only until Circular 40/2025 took effect.
  • Circular 06/2023/TT-BYT — amended Circular 15/2019; superseded with its parent.
  • Circular 15/2019/TT-BYT — issued 11 July 2019, effective 1 October 2019; replaced by Circular 07/2024.

Health insurance & reimbursement:

  • Health Insurance Law No. 25/2008/QH12 — original BHYT framework.
  • Law No. 51/2024/QH15 — amends the Health Insurance Law; passed 27 November 2024, effective 1 July 2025. Notable changes: 100% co-payment relief for participants with 5+ years of continuous coverage, four new categories eligible for state-funded contributions, and formal coverage of home-based treatment.
  • Circular 20/2022/TT-BYT — issued 31 December 2022, effective 1 March 2023. List, payment ratios, and conditions for BHYT reimbursement of chemical drugs, biologicals, radiopharmaceuticals, and tracers. Replaces Circulars 30/2018, 01/2020, and 20/2020.

Note: A draft amendment to Circular 20/2022 has been in public consultation; verify the currently effective version before relying on the appended list for commercial decisions.

Source documents

Direct links to the official text on government portals.

Primary law:

Decree:

  • Decree 24/2024/NĐ-CP — implementing the Bidding Law.

Drug-tender circular:

  • Circular 07/2024/TT-BYT — drug-tender groups, dossiers, evaluation rules at public healthcare facilities.
  • Circular 40/2025/TT-BYT — amendments to TT 07/2024 (technical specifications, plan timing).

Operational portals:

Medibase cross-references:

  • Pricing — /medicine/pricing/
  • Registration process — /medicine/registration/

Recent updates

2025 — Circular 40/2025/TT-BYT in force: Effective 25 October 2025. Fully replaces Circular 07/2024 and aligns drug tendering with the amended Pharmacy Law (44/2024/QH15). Adds rules for drug substitution when winning bid drugs are withdrawn or otherwise unavailable, and clarifies bidding for traditional medicines and medicinal materials.

2025 — Amended Health Insurance Law in force: Law 51/2024/QH15 took effect on 1 July 2025. Market-access-relevant changes: 100% co-payment relief for long-term participants, four new categories of state-funded contributors, and formal coverage of home-based treatment under BHYT.

2024 — Drug-tendering reform package: Circular 07/2024/TT-BYT (17 May 2024) replaced Circular 15/2019 and its 06/2023 amendment. Issued together with Decree 24/2024/NĐ-CP (27 February 2024), it implemented the 2023 Bidding Law for the pharmaceutical sector and aimed to address persistent drug-supply disruptions caused by tender delays at hospitals.

2024 — Bidding Law in force: Law 22/2023/QH15 took effect on 1 January 2024, replacing the 2013 Bidding Law. Article 55 establishes a specific procurement regime for medicines and medical equipment and gives public facilities greater autonomy in purchasing non-BHYT items and immunisation vaccines.

2023 — Stop-gap tendering rules: Circular 06/2023/TT-BYT amended Circular 15/2019 to address acute drug shortages — mainly simplifications around tender package preparation, plan approval, and group changes — pending the full overhaul under Circular 07/2024.

Resources & links

Government & regulator:

  • Ministry of Health (MOH) — https://moh.gov.vn — announcements on bidding-law circulars and implementation guidance.
  • Drug Administration of Vietnam (DAV) — https://dav.gov.vn — drug registration, reference biologics list, original brand-name drug (biệt dược gốc) list.
  • Vietnam Social Security (Bảo hiểm Xã hội Việt Nam) — https://baohiemxahoi.gov.vn — BHYT participation, reimbursement, and fund management.
  • National Centralized Drug Procurement Center (Trung tâm Mua sắm tập trung thuốc Quốc gia, under MOH) — list of medicines under national centralised procurement and tender results.
  • National e-Procurement System (Hệ thống mạng đấu thầu quốc gia) — https://muasamcong.mpi.gov.vn — public tender notices, plan documents, and contract awards.

Industry & analysis:

  • Vietnam Regulatory Affairs Society (VNRAS) — https://vnras.com — practitioner annotations on tendering circulars and amendments.
  • Pharma Group at EuroCham Vietnam — R&D-based industry policy dialogue on tendering and pricing.
  • Vietnam Pharmaceutical Companies Association (VNPCA).

Reference & official text:

Legal basis

See the full legal register →

Page changelog

2026-06-28: Trust-infrastructure retrofit. Document references cover the Bidding Law 22/2023/QH15 framework and the 2024–2025 drug-tender reform package (TT 07/2024 + TT 40/2025).

Effective from:
2024-01-01
Last reviewed:
2026-06-28
Page updated:
2026-08-16

Related topics — Medicines

Drug Registration Process in Vietnam

End-to-end analysis of marketing-authorisation (giấy đăng ký lưu hành) workflow at the Drug Administration of Vietnam (DAV) — legal basis, dossier requirements, evaluation steps, statutory vs real-world timelines, and practical pitfalls under the amended Pharmacy Law (44/2024/QH15, in force 1 July 2025) and Circular 12/2025/TT-BYT.

Pricing

Drug-price declaration, winning tender prices, and the price-management framework under the 2023 Price Law and the 2024 Pharmacy Law amendment.

Pharmacovigilance

Adverse drug reaction reporting, vaccine-safety surveillance, and risk management under the Drug Administration of Vietnam and the National DI & ADR Centre.

Pharmaceutical Distribution & Retail in Vietnam

Licensing for wholesalers, community pharmacies, drug shops, commune health-station drug cabinets, and traditional-medicine retailers under the post-1 July 2025 framework — the Pharmacy Business Eligibility Certificate (GCN đủ điều kiện kinh doanh dược), Good Distribution Practice (GDP), Good Pharmacy Practice (GPP), and Good Storage Practice (GSP), as reshaped by amended Pharmacy Law 44/2024/QH15 and Decree 163/2025/NĐ-CP.

Drug Import & Export in Vietnam

Two regimes — ordinary commercial trade in drugs with valid marketing authorisation, and the special import-export of drugs without registration number — under Pharmacy Law Article 60 and new Article 53a (added by Law 44/2024/QH15), Decree 163/2025/NĐ-CP Chapter IV, the Customs Law 54/2014/QH13, and the 1961 Hague Apostille Convention from 11 September 2026.

Clinical Trials & Bioequivalence in Vietnam

Authorisation, GCP, ethics review and BE-study requirements under Pharmacy Law Chapter XI as implemented by Decree 163/2025/NĐ-CP Article 23, the new Circular 50/2025/TT-BYT (effective 27 February 2026; replaces Circular 29/2018/TT-BYT, Article 9 of Circular 10/2020/TT-BYT, and Circular 08/2014/TT-BYT), Circular 43/2024/TT-BYT on ethics committees, and Circular 07/2022/TT-BYT on the BE-required substance list.

Related news — Medicine

Back to Medicines

Reference information only; not legal or medical advice.